Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models

Extrinsic pathway agonists have failed repeatedly in the clinic for three core reasons: Inefficient ligand-induced receptor multimerization, poor pharmacokinetic properties, and tumor intrinsic resistance. Here, we address these factors by (i) using a highly potent death receptor agonist (DRA), (ii)...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzari, Mandana T., Anderson, Grace R., Lin, Kevin H., Soderquist, Ryan S., Çakir, Merve, Zhang, Mitchell, Moore, Chandler E., Skelton, Rachel N., Fèvre, Maréva, Li, Xinghai, Bellucci, Joseph J., Wardell, Suzanne E., Costa, Simone A., Wood, Kris C., Chilkoti, Ashutosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726446/
https://www.ncbi.nlm.nih.gov/pubmed/31517048
http://dx.doi.org/10.1126/sciadv.aaw9162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726446/
https://www.ncbi.nlm.nih.gov/pubmed/31517048
http://dx.doi.org/10.1126/sciadv.aaw9162

Ejemplares similares